Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C

T Suou1, K Hosho, Y Kishimoto

  • 1Second Department of Internal Medicine, Tottori University Faculty of Medicine, Japan.

Hepatology (Baltimore, Md.)
|August 1, 1995
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanism of haematuria in lupus nephritis.

Annals of the rheumatic diseases·1995
Same author

[Prevalence and transmission of hepatitis C virus in polluted area in Japan].

Nihon rinsho. Japanese journal of clinical medicine·1995
Same author

[Changes of serum 2',5'-oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C].

Nihon rinsho. Japanese journal of clinical medicine·1995
Same author

Use of haloacetate dehalogenase genes as selection markers for Escherichia coli and Pseudomonas vectors.

Biodegradation·1995
Same author

Diagnosis of vascular compression in facial spasm by stereoscopic short-range magnetic resonance angiography. Technical note.

Journal of neurosurgery·1995
Same author

The effect of a TXA2 receptor antagonist ON-579 on experimental allergic reactions.

Prostaglandins, leukotrienes, and essential fatty acids·1995

Interferon alfa (IFN-alpha) treatment significantly reduces hepatic fibrosis markers in chronic hepatitis C patients. This antifibrotic effect is sustained long-term, potentially preventing cirrhosis progression.

Area of Science:

  • Hepatology
  • Virology
  • Biochemistry

Background:

  • Chronic hepatitis C leads to hepatic extracellular matrix deposition and fibrosis.
  • Interferon alfa (IFN-alpha) is a treatment for chronic hepatitis C.
  • Assessing IFN-alpha's impact on fibrogenesis is crucial for understanding long-term outcomes.

Purpose of the Study:

  • To evaluate the effect of interferon alfa (IFN-alpha) on hepatic extracellular matrix in chronic hepatitis C.
  • To investigate changes in serum N-terminal propeptide of type III procollagen (PIIINP) during and after IFN-alpha therapy.

Main Methods:

  • A study involving 178 treated and 45 non-treated patients with chronic hepatitis C.
  • Serum PIIINP levels were measured before, during, and after a 4-month IFN-alpha treatment course.

Related Experiment Videos

  • Serum transaminase levels were also monitored for comparison.

    • Main Results:

    • Serum PIIINP levels were significantly higher in nonresponders compared to responders pre-treatment.
    • IFN-alpha treatment led to a significant decrease in serum PIIINP levels, sustained for 12 months post-treatment.
    • The decrease in PIIINP was more pronounced in patients with elevated baseline levels and correlated better with initial levels than transaminase changes.

    Conclusions:

    • IFN-alpha treatment induces long-term suppression of active fibrogenesis in chronic hepatitis C.
    • This antifibrotic effect is independent of antiviral and anti-necroinflammatory actions.
    • IFN-alpha therapy may prevent the progression of chronic hepatitis C to cirrhosis.